FogPharma Stock
FogPharma develops cell-penetrating mini proteins (CPMPs) designed to target and neutralize cancer-causing proteins within cancer cells. These innovative therapeutics aim to treat cancer-related diseases by reaching targets that conventional treatments cannot address.
Founded: 2015
FogPharma Company Overview
null
Management Team
| Mathai Mammen Ph.D. Chief Executive Officer, President & Chairman |
| Kristen Stants Chief People Officer |
| Gregory Miller Chief Business Officer |
| Brandon Allgood Ph.D. Chief Data Officer |
| Keith Orford MD Chief Medical Officer & Executive Vice President of Clinical and Translational Science |
| John McGee Ph.D. Scientific Co-Founder, Vice President of De Novo Discovery & Head of De Novo Discovery |
| Weiqing Zhou Co-Founder & Chief Operating Officer |
| Rohin Mhatre Ph.D. Chief Technical Operations Officer & Executive Vice President |
| Gregory Verdine Ph.D. Co-Founder, Vice Chairman & Special Advisor |
